When asked if he carries any responsibility for the opioid crisis in the United States, Richard Sackler firmly replied: ‘No’
THURSDAY, Aug. 19, 2021 (HealthDay News) — The former president and co-chairman of Purdue Pharma said Wednesday that his family and the company bear no responsibility for the opioid crisis in the United States.
Richard Sackler, M.D., made his comments in testimony delivered by video during a federal bankruptcy court confirmation hearing for a plan to restructure Purdue and settle all lawsuits against the company and family members for their part in the opioid epidemic, The New York Times reported.
He was asked: “Do you have any responsibility for the opioid crisis in the United States?”
“No,” Sackler, 76, replied.
“Does the Sackler family have any responsibility for the opioid crisis in the United States?”
“No,” Sackler again replied.
“Does Purdue Pharma have any responsibility for the opioid crisis in the United States?”
More firmly: “No.”
For nearly 20 years, Sackler was the lead family member in the Sackler-owned prescription opioid maker’s efforts to sell its signature prescription painkiller, OxyContin.
Sackler was called to appear for questioning by lawyers for states that oppose the settlement plan. One objection the states have is that in exchange for paying $4.5 billion, the Sacklers will receive legal protections that are too broad, The Times reported.
During Sackler’s tenure, Purdue Pharma twice pleaded guilty to federal criminal charges related to marketing and sales of OxyContin and reached a settlement with the state of Kentucky. It was just one of many settlements made by the company.
CDC: Buprenorphine Treatment Differs in Urban, Rural Areas
Breathing Interventions May Curb Cravings With Substance Use
Adding Cognitive Behavioral Therapy, Self-Management Does Not Improve Opioid Taper Success
About 30 Percent of Pediatric Surgery Patients Receive Opioid Rx
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children
Robotic Arm-Assisted TKR Offers Similar Outcome to Conventional TKR
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors
Safety Intervention Reduces Incidence of Postoperative Endophthalmitis